Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias P Wymann

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Molecular Biology of the Cell|January 8, 2010
Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertilityElisa Ciraolo, Fulvio Morello, Robin M Hobbs, et al.
Molecular and Cellular Biology|July 23, 2008
The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expressionRosaline C-Y Hui, Ana R Gomes, Demetra Constantinidou, et al.
European Journal of Medicinal Chemistry|January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitorMartina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Nature Communications|July 2, 2025
PI3Kγ signaling controls trafficking of CD8<sup>+</sup> T cells between lymphoid and non-lymphoid organs and drives hypertension in a murine modelMarialuisa Perrotta, Sara Perrotta, Lorenzo Carnevale, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Circulation|February 13, 2008
Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processesAnne Fougerat, Stéphanie Gayral, Pierre Gourdy, et al.
Chemical Science|November 21, 2024
Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signalingLukas Bissegger, Theodora A Constantin, Erhan Keles, et al.
The Journal of Experimental Medicine|July 31, 2014
Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 responseNatalia F Smirnova, Stéphanie Gayral, Christophe Pedros, et al.
The EMBO Journal|August 20, 2004
Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient miceAnnalisa Del Prete, William Vermi, Erica Dander, et al.
Journal of Medicinal Chemistry|November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological DisordersChiara Borsari, Erhan Keles, Denise Rageot, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Molecular Biology of the Cell|January 8, 2010
Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertilityElisa Ciraolo, Fulvio Morello, Robin M Hobbs, et al.
Molecular and Cellular Biology|July 23, 2008
The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expressionRosaline C-Y Hui, Ana R Gomes, Demetra Constantinidou, et al.
European Journal of Medicinal Chemistry|January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitorMartina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Nature Communications|July 2, 2025
PI3Kγ signaling controls trafficking of CD8<sup>+</sup> T cells between lymphoid and non-lymphoid organs and drives hypertension in a murine modelMarialuisa Perrotta, Sara Perrotta, Lorenzo Carnevale, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Circulation|February 13, 2008
Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processesAnne Fougerat, Stéphanie Gayral, Pierre Gourdy, et al.
Chemical Science|November 21, 2024
Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signalingLukas Bissegger, Theodora A Constantin, Erhan Keles, et al.
The Journal of Experimental Medicine|July 31, 2014
Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 responseNatalia F Smirnova, Stéphanie Gayral, Christophe Pedros, et al.
The EMBO Journal|August 20, 2004
Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient miceAnnalisa Del Prete, William Vermi, Erica Dander, et al.
Journal of Medicinal Chemistry|November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological DisordersChiara Borsari, Erhan Keles, Denise Rageot, et al.
Pageof 8